Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease

Autor: Dale L. Nepert, David R. Spigel, Margarita Majem, Fred J. Kudrik, Santiago Ponce, Mark A. Socinski, Peter M. Ellis, Paul Lorigan, Jesus Corral, Frederic J. Kaye, Leena Gandhi, Martin Gutierrez, Luis Gonzaga Paz Ares

Publikováno v: Clinical Lung Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Repisalud
Instituto de Salud Carlos III (ISCIII)
Socinski, M A, Kaye, F J, Spigel, D R, Kudrik, F J, Ponce, S, Ellis, P M, Majem, M, Lorigan, P, Gandhi, L, Gutierrez, M E, Nepert, D, Corral, J & Paz-Ares, L 2017, ' Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. ', Clinical Lung Cancer, vol. 18, no. 1, PMID: 2834110, pp. 68-76 . https://doi.org/10.1016/j.cllc.2016.09.002

Lorvotuzumab mertansine (LM, IMGN901) is a CD56-targeting antibody-drug conjugate developed for tumor-selective delivery of the cytotoxic maytansinoid DM1. This phase 1/2 study evaluated the combination of LM with first-line carboplatin/etoposide che

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac929c5bd80dd3465fd3229718f3bad6
https://doi.org/10.1016/j.cllc.2016.09.002